Cargando…
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has represented the standard of care for advanced HCC for almost 10 years, offering a survival benefit when compared to pla...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260177/ https://www.ncbi.nlm.nih.gov/pubmed/34239844 http://dx.doi.org/10.2147/JHC.S285726 |